Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.1213 | 0.3623 | 0.5 |
Brugia malayi | Copper type II ascorbate-dependent monooxygenase, N-terminal domain containing protein | 0.0616 | 0.0107 | 0.0294 |
Brugia malayi | Copper type II ascorbate-dependent monooxygenase, C-terminal domain containing protein | 0.1213 | 0.3623 | 1 |
Echinococcus multilocularis | peptidyl glycine alpha amidating monooxygenase | 0.1213 | 0.3623 | 0.5 |
Brugia malayi | Copper type II ascorbate-dependent monooxygenase, C-terminal domain containing protein | 0.1213 | 0.3623 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.1213 | 0.3623 | 0.5 |
Echinococcus granulosus | peptidyl glycine alpha amidating monooxygenase | 0.1213 | 0.3623 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
AUC (ADMET) | = 716.9 ug hr ml-1 | Area under the curve measured after intravenous bolus administration of 50 mg/kg of compound to rats | ChEMBL. | 14584952 |
CL (ADMET) | = 70 ml hr-1 kg-1 | Clearance measured after intravenous bolus administration of 50 mg/kg of compound to rats | ChEMBL. | 14584952 |
Cmax (ADMET) | = 54.6 ug ml-1 | Maximum plasma concentration measured after intravenous bolus administration of 50 mg/kg of compound to rats | ChEMBL. | 14584952 |
Solubility | = 141 mg ml-1 | Solubility of the compound was measured in saline at 25 degree C | ChEMBL. | 14584952 |
Survival (functional) | = 90 % | Anti-microbial activity against Staphylococcus aureus measured as percent survival of mice 1 hr post challenge | ChEMBL. | 14584952 |
Survival (functional) | = 90 % | Anti-microbial activity against Staphylococcus aureus measured as percent survival of mice 1 hr post challenge | ChEMBL. | 14584952 |
T1/2 (ADMET) | = 9.12 hr | Circulatory half life measured after intravenous bolus administration of 50 mg/kg of compound to rats | ChEMBL. | 14584952 |
T1/2 (ADMET) | > 24 hr | Half-life of the compound was determined in rat plasma | ChEMBL. | 14584952 |
T1/2 (ADMET) | >> 24 hr | Half-life of the compound was determined in human plasma | ChEMBL. | 14584952 |
Vss (ADMET) | = 1648.3 ml kg-1 | Volume of distribution at a steady state measured after intravenous bolus administration of 50 mg/kg of compound to rats | ChEMBL. | 14584952 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.